News

Austin Health ID to join the Doherty Institute

18 March 2019 | Announcement from Professor Sharon Lewin, Director, Doherty Insititute: I am thrilled to announce that Austin Health’s Infectious Diseases Department (Austin Health ID) is joining the Peter Doherty Institute for Infection and Immunity (Doherty Institute)…

The Global Health Alliance Welcomes Labor’s Pacific Avoidable Blindness and Vision Loss Fund 

14 March 2018 The Senator Hon Penny Wong announced that if elected, a Labor Government will invest $32 million in a Pacific Avoidable Blindness and Vision Loss Fund. “At a time when Australia’s focus is returning to the…

Media release: Victorian medtech startups to get strategy boost for entering the US healthcare market

14 March 2019 | A new program to help Victorian medtech startups enter the US market is being launched next week in Melbourne. Healthtech Reimbursement: Getting Paid in the USA has been developed by BioMelbourne Network, with support…

New space for Outerspace Melbourne

8 March 2019 | Outerspace Melbourne has settled in the new makerspace in Abbotsford, a short drive from the old studio. The team enjoyed designing the “clean slate” space and making it their own, with an open layout…

Immutep presents positive IMP761 preclinical results

8 March 2019 | Immutep today announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of autoimmune diseases. The results were presented at the 14th Congress of European…

Immutep doses first patient in TACTI-002 Phase II trial

8 March 2019 | Immutep has just announced that the first patient has been dosed in a new Phase II clinical trial (TACTI-002) which will evaluate the combination of their lead product candidate, eftilagimod alpha (“efti”), and KEYTRUDA®…

Immutep announces data from ongoing TACTI-mel Phase I clinical trial in unresectable or metastatic melanoma

8 March 2019 | This week at the World Immunotherapy Congress 2019 in San Diego USA, Immutep announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the company’s lead product candidate, eftilagimod alpha…

Mayne Pharma treatment for chronic breathlessness approved by TGA

20 February 2019 | Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the Therapeutic Goods Administration (TGA) has approved KAPANOL® low dose sustained-release 10mg and 20mg morphine capsules for the treatment of chronic breathlessness in…

Nominations open for the Bionics Institute Award for Excellence in Medical Device Innovation

15 February 2019 | Nominations are now open for the Bionics Institute Award for Excellence in Medical Device Innovation. The 2019 Bionics Institute Award acknowledges an individual who, through their innovation, has made a significant impact on the…

Cartherics and panCELLa announce collaborative agreement to develop pluripotent cell lines for cell therapy

13 February 2019  Cartherics and panCELLa are pleased to announce their collaboration to research, develop and commercialise products for the treatment of cancer and other debilitating diseases using cell therapy. panCELLa will integrate their exclusive FailSafeTM technology into Cartherics’ proprietary…

Nucleus Network expands early phase trial capacity in Australia with acquisition of Q-Pharm

11 February 2019 Nucleus Network recently announced its acquisition of Q-Pharm, a 62-bed dedicated early-phase clinical trial facility based in the Herston health precinct in Brisbane. Q-Pharm was previously wholly owned by the QIMR Berghofer Medical Research Institute.…

4th Annual CEO Remuneration Report – Wexford Hayes

31 January 2019 This 4th annual CEO Remuneration report reviews the remuneration of the top 100 public companies listed on the Australian Securities Exchange for the Health Care & Biotechnology Sector. The report provides insight into remuneration in…

Home

News & opinion

Member Directory

Events